{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T10:37:07Z","timestamp":1648809427888},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T00:00:00Z","timestamp":1596067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Schmerz"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1007\/s00482-020-00487-5","type":"journal-article","created":{"date-parts":[[2020,7,30]],"date-time":"2020-07-30T08:04:38Z","timestamp":1596096278000},"page":"447-459","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Schmerztherapie bei seltenen Erkrankungen"],"prefix":"10.1007","volume":"34","author":[{"given":"D.","family":"Emmert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Heuchemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Sellin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Reimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Cuhls","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Kornblum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Conrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"M\u00fccke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,30]]},"reference":[{"key":"487_CR1","unstructured":"Nationales Aktionsb\u00fcndnis f\u00fcr Menschen mit Seltenen Erkrankungen Seltene Erkrankungen. https:\/\/www.namse.de\/zum-aktionsbuendnis\/ueber-seltene-erkrankungen. Zugegriffen: 21. Nov. 2019"},{"key":"487_CR2","unstructured":"orpha.net Was ist ein Orphan Drug? https:\/\/www.orpha.net\/consor\/cgi-bin\/Education_AboutOrphanDrugs.php?lng=DE. Zugegriffen: 21. Nov. 2019"},{"key":"487_CR3","first-page":"1","volume-title":"Harrisons Innere Medizin","year":"2016","unstructured":"Kasper\u00a0DL, Fauci\u00a0AS, Hauser\u00a0SL, Longo\u00a0DL, Jameson\u00a0JL, Loscalzo\u00a0JL et al (Hrsg) (2016) Harrisons Innere Medizin, 19.\u00a0Aufl. McGraw-Hill, New York, NY, S 1 (Register)","edition":"19"},{"issue":"S3","key":"487_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00508-015-0872-x","volume":"127","author":"I Pabinger","year":"2015","unstructured":"Pabinger\u00a0I, Heistinger\u00a0M, Muntean\u00a0W, Reitter-Pfoertner\u00a0S\u2011E, Rosenlechner\u00a0S, Schindl\u00a0T et al (2015) H\u00e4mophiliebehandlung in \u00d6sterreich. Wien Klin Wochenschr 127(S3):115\u2013130","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"487_CR5","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","volume":"19","author":"A Srivastava","year":"2013","unstructured":"Srivastava\u00a0A, Brewer\u00a0AK, Mauser-Bunschoten\u00a0EP, Key\u00a0NS, Kitchen\u00a0S, Llinas\u00a0A et al (2013) Guidelines for the management of hemophilia. Haemophilia 19(1):e1\u201347","journal-title":"Haemophilia"},{"issue":"6","key":"487_CR6","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s00482-018-0321-7","volume":"32","author":"W Stromer","year":"2018","unstructured":"Stromer\u00a0W, Messerer\u00a0B, Crevenna\u00a0R, Hemberger\u00a0SH, Jauk\u00a0B, Schwarz\u00a0R et\u00a0al (2018) Schmerztherapie bei Kindern und Jugendlichen mit H\u00e4mophilie: Handlungsempfehlungen einer Expertengruppe. Schmerz 32(6):404\u2013418","journal-title":"Schmerz"},{"key":"487_CR7","volume-title":"Kurzlehrbuch Pharmakologie und Toxikologie","author":"T Herdegen","year":"2014","unstructured":"Herdegen\u00a0T (2014) Kurzlehrbuch Pharmakologie und Toxikologie, 3.\u00a0Aufl. Thieme, Stuttgart New York","edition":"3"},{"key":"487_CR8","unstructured":"https:\/\/www.aspirin.de\/static\/documents\/aspirin-500mg-ueberzogene-tabletten-beipackzettel.pdf. Zugegriffen: Mai 2020"},{"key":"487_CR9","unstructured":"S2k-Leitlinie Synovitis bei H\u00e4mophilie. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/086-005l_S2k_Synovitis-bei-Haemophilie_2019-07.pdf. Zugegriffen: 3. Jan. 2020"},{"key":"487_CR10","unstructured":"https:\/\/www.haemcare.de\/wp-content\/uploads\/Novo-Nordisk-Haemophilie-Klinikleitfaden-704253.pdf. Zugegriffen: Mai 2020"},{"issue":"7","key":"487_CR11","doi-asserted-by":"publisher","first-page":"84","DOI":"10.17116\/terarkh201688784-88","volume":"88","author":"OK Levchenko","year":"2016","unstructured":"Levchenko\u00a0OK, Shulutko\u00a0EM, Zorenko\u00a0VY, Galstyan\u00a0GM (2016) The specific features of pain syndrome in patients with hemophilia. Ter Arkh 88(7):84","journal-title":"Ter Arkh"},{"key":"487_CR12","unstructured":"Fachinformation Pregabalin Hartkapseln. https:\/\/www.pfizermed.de\/fileadmin\/produktdatenbank\/pdf\/022009_freigabe.pdf. Zugegriffen: 27. Dez. 2019"},{"key":"487_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-662-49546-9_90-1","volume-title":"Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie","author":"RA Rupec","year":"2016","unstructured":"Rupec\u00a0RA (2016) Purin\u2011, Sphingolipid- und Aminos\u00e4urestoffwechselst\u00f6rungen. In: Plewig\u00a0G, Ruzicka\u00a0T, Kaufmann\u00a0R, Hertl\u00a0M (Hrsg) Braun-Falco\u2019s Dermatologie, Venerologie und Allergologie. Springer, Berlin Heidelberg, S 1\u201312 https:\/\/doi.org\/10.1007\/978-3-662-49546-9_90-1"},{"key":"487_CR14","volume-title":"Innere Medizin","author":"G Herold","year":"2019","unstructured":"Herold\u00a0G et\u00a0al (2019) Innere Medizin. Gerd Herold, K\u00f6ln"},{"key":"487_CR15","unstructured":"Interdisziplin\u00e4re Leitlinie f\u00fcr die Diagnose und Therapie des Morbus Fabry. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/030-134l_S2k_Morbus_Fabry_Diagnose_Therapie_2013-abgelaufen.pdf. Zugegriffen: 26. Nov. 2019"},{"issue":"5","key":"487_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s00482-012-1238-1","volume":"26","author":"N \u00dc\u00e7eyler","year":"2012","unstructured":"\u00dc\u00e7eyler\u00a0N, Sommer\u00a0C (2012) Morbus Fabry: Diagnostik und Therapie. Schmerz 26(5):609\u2013619","journal-title":"Schmerz"},{"issue":"4","key":"487_CR17","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","volume":"123","author":"A Ortiz","year":"2018","unstructured":"Ortiz\u00a0A, Germain\u00a0DP, Desnick\u00a0RJ, Politei\u00a0J, Mauer\u00a0M, Burlina\u00a0A et\u00a0al (2018) Fabry disease revisited: management and treatment recommendations for adult patients. Mol Genet Metab 123(4):416\u2013427","journal-title":"Mol Genet Metab"},{"issue":"6","key":"487_CR18","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/GIM.0b013e3181a23bec","volume":"11","author":"C Whybra","year":"2009","unstructured":"Whybra\u00a0C, Miebach\u00a0E, Mengel\u00a0E, Gal\u00a0A, Baron\u00a0K, Beck\u00a0M et al (2009) A 4\u2011year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry disease. Genet Med 11(6):441\u2013449","journal-title":"Genet Med"},{"key":"487_CR19","unstructured":"Sch\u00f6ls\u00a0L et al (2017) S1-Leitlinie Leukodystrophien und heredit\u00e4re Leukencephalopathien im Erwachsenenalter. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. www.dgn.org\/leitlinien. Zugegriffen: 08.07.2020"},{"key":"487_CR20","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2377-11-61","volume":"11","author":"AP Burlina","year":"2011","unstructured":"Burlina\u00a0AP, Sims\u00a0KB, Politei\u00a0JM, Bennett\u00a0GJ, Baron\u00a0R, Sommer\u00a0C et\u00a0al (2011) Early diagnosis of peripheral nervous system involvement in Fabry disease and treatment of neuropathic pain: the report of an expert panel. BMC Neurol 11:61\u201361","journal-title":"BMC Neurol"},{"issue":"1","key":"487_CR21","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00108-012-3204-5","volume":"54","author":"C Sommer","year":"2013","unstructured":"Sommer\u00a0C, \u00dc\u00e7eyler\u00a0N, Duning\u00a0T, Arning\u00a0K, Baron\u00a0R, Brand\u00a0E et\u00a0al (2013) Schmerztherapie bei Morbus Fabry. Internist 54(1):121\u2013130","journal-title":"Internist"},{"issue":"10","key":"487_CR22","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1185\/030079906X132488","volume":"22","author":"R Freynhagen","year":"2006","unstructured":"Freynhagen\u00a0R, Baron\u00a0R, Gockel\u00a0U, T\u00f6lle\u00a0TR (2006) pain DETECT\u202f: a\u00a0new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin 22(10):1911\u20131920","journal-title":"Curr Med Res Opin"},{"key":"487_CR23","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/978-3-642-40740-6_4","volume-title":"Weiterbildung Schmerzmedizin: CME-Beitr\u00e4ge aus: Der Schmerz Januar 2012\u2013Juni 2013","author":"N \u00dc\u00e7eyler","year":"2013","unstructured":"\u00dc\u00e7eyler\u00a0N, Sommer\u00a0C (2013) Morbus Fabry. In: G\u00f6bel\u00a0H, Sabatowski\u00a0H (Hrsg) Weiterbildung Schmerzmedizin: CME-Beitr\u00e4ge aus: Der Schmerz Januar 2012\u2013Juni 2013. Springer, Berlin, Heidelberg, S 31\u201340 https:\/\/doi.org\/10.1007\/978-3-642-40740-6_4"},{"issue":"1","key":"487_CR24","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s12883-016-0549-8","volume":"16","author":"Y Schuller","year":"2016","unstructured":"Schuller\u00a0Y, Linthorst\u00a0GE, Hollak\u00a0CEM, Van Schaik\u00a0IN, Biegstraaten\u00a0M (2016) Pain management strategies for neuropathic pain in Fabry disease\u2014a\u00a0systematic review. BMC Neurol 16(1):25","journal-title":"BMC Neurol"},{"key":"487_CR25","doi-asserted-by":"publisher","first-page":"205873841983838","DOI":"10.1177\/2058738419838383","volume":"33","author":"E Cavalli","year":"2019","unstructured":"Cavalli\u00a0E, Mammana\u00a0S, Nicoletti\u00a0F, Bramanti\u00a0P, Mazzon\u00a0E (2019) The neuropathic pain: an overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol 33:205873841983838","journal-title":"Int J Immunopathol Pharmacol"},{"key":"487_CR26","unstructured":"Kommission Leitlinien der Deutschen Gesellschaft f\u00fcr Neurologie (2015) Myositissyndrome \u2013 Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie. https:\/\/www.awmf.org\/uploads\/tx_szleitlinien\/030-054l_S2k_Myositissyndrome_2015-08-abgelaufen.pdf. Zugegriffen: 26. Nov. 2019"},{"issue":"9250","key":"487_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/S0140-6736(00)03540-6","volume":"357","author":"CL Hill","year":"2001","unstructured":"Hill\u00a0CL, Zhang\u00a0Y, Sigurgeirsson\u00a0B, Pukkala\u00a0E, Mellemkjaer\u00a0L, Airio\u00a0A et al (2001) Frequency of specific cancer types in dermatomyositis and polymyositis: a\u00a0population-based study. Lancet 357(9250):96\u2013100","journal-title":"Lancet"},{"issue":"S1","key":"487_CR28","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s00105-018-4195-5","volume":"69","author":"I Goldscheider","year":"2018","unstructured":"Goldscheider\u00a0I, von Braunm\u00fchl\u00a0T, Jansson\u00a0A, Ruzicka\u00a0T (2018) Blaschkoide juvenile amyopathische Dermatomyositis. Hautarzt 69(S1):68\u201370","journal-title":"Hautarzt"},{"key":"487_CR29","unstructured":"Altmeyer P Interface-Dermatitis. In: Altmeyers Enzyklop\u00e4die. https:\/\/www.enzyklopaedie-dermatologie.de\/dermatologie\/interface-dermatitis-14645. Zugegriffen: 26. Nov. 2019"},{"issue":"9","key":"487_CR30","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1093\/rheumatology\/keu024","volume":"53","author":"L Unger","year":"2014","unstructured":"Unger\u00a0L, Kampf\u00a0S, L\u00fcthke\u00a0K, Aringer\u00a0M (2014) Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a\u00a0real-life population. Rheumatology 53(9):1630\u20131638","journal-title":"Rheumatology"},{"key":"487_CR31","unstructured":"UpToDate Approach to the patient with myalgia. https:\/\/www.uptodate.com\/contents\/approach-to-the-patient-with-myalgia?search=myalgia&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1#H16. Zugegriffen: 23. Dez. 2019"},{"key":"487_CR32","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/BOR.0b013e32834f19f5","volume":"24","author":"H Alexanderson","year":"2011","unstructured":"Alexanderson\u00a0H, Lundberg\u00a0I (2011) Exercise as a\u00a0therapeutic modality in patients with idiopathic inflammatory myopathies. Curr Opin Rheumatol 24:201\u2013207","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"487_CR33","doi-asserted-by":"publisher","first-page":"101433","DOI":"10.1016\/j.berh.2019.101433","volume":"33","author":"S Glaubitz","year":"2019","unstructured":"Glaubitz\u00a0S, Schmidt\u00a0K, Zsch\u00fcntzsch\u00a0J, Schmidt\u00a0J (2019) Myalgia in myositis and myopathies. Best Pract Res Clin Rheumatol 33(3):101433","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"4","key":"487_CR34","doi-asserted-by":"publisher","first-page":"482","DOI":"10.3899\/jrheum.160763","volume":"44","author":"K Noda","year":"2017","unstructured":"Noda\u00a0K, Yoshida\u00a0K, Ukichi\u00a0T, Furuya\u00a0K, Hirai\u00a0K, Kingetsu\u00a0I et\u00a0al (2017) Myalgia in patients with dermatomyositis and polymyositis is attributable to fasciitis rather than myositis: a retrospective study of 32 patients who underwent histopathological examinations. J\u00a0Rheumatol 44(4):482\u2013487","journal-title":"J Rheumatol"},{"issue":"4","key":"487_CR35","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s13311-018-00675-3","volume":"15","author":"J Hamel","year":"2018","unstructured":"Hamel\u00a0J, Tawil\u00a0R (2018) Facioscapulohumeral muscular dystrophy: update on pathogenesis and future treatments. Neurotherapeutics 15(4):863\u2013871","journal-title":"Neurotherapeutics"},{"issue":"3","key":"487_CR36","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1002\/mus.25991","volume":"57","author":"G Mor\u00eds","year":"2018","unstructured":"Mor\u00eds\u00a0G, Wood\u00a0L, Fern\u00e1ndez-Torr\u00f3n\u00a0R, Gonz\u00e1lez Coraspe\u00a0JA, Turner\u00a0C, Hilton-Jones\u00a0D et al (2018) Chronic pain has a\u00a0strong impact on quality of life in facioscapulohumeral muscular dystrophy: pain and QoL in FSHD. Muscle Nerve 57(3):380\u2013387","journal-title":"Muscle Nerve"},{"issue":"2","key":"487_CR37","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.apmr.2007.08.153","volume":"89","author":"MP Jensen","year":"2008","unstructured":"Jensen\u00a0MP, Hoffman\u00a0AJ, Stoelb\u00a0BL, Abresch\u00a0RT, Carter\u00a0GT, McDonald\u00a0CM (2008) Chronic pain in persons with myotonic dystrophy and facioscapulohumeral dystrophy. Arch Phys Med Rehabil 89(2):320\u2013328","journal-title":"Arch Phys Med Rehabil"},{"issue":"2","key":"487_CR38","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/mus.21308","volume":"40","author":"L Padua","year":"2009","unstructured":"Padua\u00a0L, Aprile\u00a0I, Frusciante\u00a0R, Iannaccone\u00a0E, Rossi\u00a0M, Renna\u00a0R et\u00a0al (2009) Quality of life and pain in patients with facioscapulohumeral muscular dystrophy. Muscle Nerve 40(2):200\u2013205","journal-title":"Muscle Nerve"},{"key":"487_CR39","volume-title":"Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie","author":"R Lindemuth","year":"2017","unstructured":"Lindemuth\u00a0R et al (2017) S1-Leitlinie Crampi\/Muskelkrampf. In: Deutsche Gesellschaft f\u00fcr Neurologie (Hrsg) Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie (Online: www.dgn.org\/leitlinien (abgerufen am 22.05.2020))"},{"issue":"1","key":"487_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.2522\/ptj.20070104","volume":"88","author":"S Pandya","year":"2008","unstructured":"Pandya\u00a0S, King\u00a0WM, Tawil\u00a0R (2008) Facioscapulohumeral dystrophy. Phys Ther 88(1):105\u2013113","journal-title":"Phys Ther"},{"key":"487_CR41","unstructured":"(2019) Fazioskapulohumerale Dystrophie. https:\/\/www.orpha.net\/data\/patho\/Pub\/de\/ACHSE_PAtid62_Fazioskapulohumerale.pdf. Zugegriffen: Mai 2020"},{"issue":"7","key":"487_CR42","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00415-006-0432-4","volume":"254","author":"EL Kooi","year":"2007","unstructured":"Kooi\u00a0EL, Kalkman\u00a0JS, Lindeman\u00a0E, Hendriks\u00a0JCM, Engelen\u00a0BGM, Bleijenberg\u00a0G et\u00a0al (2007) Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy. J\u00a0Neurol 254(7):931\u2013940","journal-title":"J Neurol"},{"issue":"7","key":"487_CR43","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.nmd.2010.04.007","volume":"20","author":"R Tawil","year":"2010","unstructured":"Tawil\u00a0R, van der Maarel\u00a0S, Padberg\u00a0GW, van Engelen\u00a0BGM (2010) 171st ENMC international workshop: standards of care and management of facioscapulohumeral muscular dystrophy. Neuromuscul Disord 20(7):471\u2013475","journal-title":"Neuromuscul Disord"}],"container-title":["Der Schmerz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-020-00487-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00482-020-00487-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00482-020-00487-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T23:34:21Z","timestamp":1627601661000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00482-020-00487-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,30]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["487"],"URL":"https:\/\/doi.org\/10.1007\/s00482-020-00487-5","relation":{},"ISSN":["0932-433X","1432-2129"],"issn-type":[{"value":"0932-433X","type":"print"},{"value":"1432-2129","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,30]]},"assertion":[{"value":"30 July 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>D.\u00a0Emmert<\/b>: A.\u00a0Finanzielle Interessen: D.\u00a0Emmert gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Student der Humanmedizin im PJ, Universit\u00e4tsklinikum Bonn | SHK bis 03\/2019, Zentrum f\u00fcr seltene Erkrankungen in Bonn (ZSEB). <b>L.\u00a0Heuchemer<\/b>: A.\u00a0Finanzielle Interessen: L.\u00a0Heuchemer gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Studentische Hilfskraft, Zentrum f\u00fcr seltene Erkrankungen in Bonn. <b>J.\u00a0Sellin<\/b>: A.\u00a0Finanzielle Interessen: J.\u00a0Sellin gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Wissenschaftliche Mitarbeiterin, Zentrum f\u00fcr seltene Erkrankungen, Universit\u00e4tsklinikum Bonn | Mitgliedschaften: Gesellschaft f\u00fcr Biochemie und Molekularbiologie (GBM), Deutscher Hochschulverband. <b>J.\u00a0Reimann<\/b>: A.\u00a0Finanzielle Interessen: Referent, Vortragshonorar: Firma Natus Europe. \u2013 B.\u00a0Nichtfinanzielle Interessen: Arzt f\u00fcr Neurologie, Oberarzt, Klinik und Poliklinik f\u00fcr Neurologie, Universit\u00e4tsklinikum Bonn | Mitgliedschaften: Referenzzentrum neuromuskl\u00e4re Erkrankungen der DGNN, World Muscle Society, European Academy of Neurology. <b>H.\u00a0Cuhls<\/b>: A.\u00a0Finanzielle Interessen: H.\u00a0Cuhls gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Leitender Oberarzt, stellvertretender Direktor, Klinik und Poliklinik f\u00fcr Palliativmedizin, Bonn | Mitgliedschaften: Bund deutscher An\u00e4sthesisten (BDA), Deutsche Gesellschaft f\u00fcr An\u00e4sthesiologie und Intensivmedizin (DGAI), Deutsche Schmerzgesellschaft, Deutsche Gesellschaft f\u00fcr Palliativmedizin (DGP). <b>C.\u00a0Kornblum<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Travel Funding (Investigator Meeting) und Forschungsf\u00f6rderung: Primary Investigator, ReDUX4 Studie, Fulcrum Therapeutics USA (FSHD). \u2013 Referentenhonorar oder Kostenerstattung als passiver Teilnehmer: Travel Funding (Investigator Meeting): ReDUX4 Studie, Fulcrum Therapeutics USA (FSHD). \u2013 B.\u00a0Nichtfinanzielle Interessen: Ober\u00e4rztin der Klinik und Poliklinik f\u00fcr Neurologie, Universit\u00e4tsklinikum Bonn, Leitung der Sektion Neuromuskul\u00e4re Erkrankungen | Mit-Koordinatorin des MITONET, Deutsches Netzwerk f\u00fcr mitochondriale Erkrankungen, BMBF-F\u00f6rderung translationsorientierter Verbundvorhaben im Bereich der seltenen Erkrankungen | Representative des Health Care Providers Universit\u00e4tsklinikum Bonn, Germany (HCP19), Europ\u00e4isches Referenznetzwerk ERN EURO-NMD | Sprecherin des Zentrums f\u00fcr seltene neurologische Bewegungsst\u00f6rungen, Epilepsien und Muskelerkrankungen (B-Zentrum) des Zentrums f\u00fcr seltene Erkrankungen Bonn (ZSEB) | Leitung des Muskelzentrums Bonn des Muskelzentrums Nordrhein der Deutschen Gesellschaft f\u00fcr Muskelkranke e.\u202fV. | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Neurologie (DGN), Kommission Neuromuskul\u00e4re Erkrankungen und Motoneuronerkrankungen der DGN, Deutsche Gesellschaft f\u00fcr Klinische Neurophysiologie und funktionelle Bildgebung (DGKN), Deutsche Gesellschaft f\u00fcr Ultraschall in der Medizin (DEGUM e.\u202fV.), Sektion Neurologie und Arbeitsgruppe vaskul\u00e4rer Ultraschall (AvU), Deutsche Gesellschaft f\u00fcr Muskelkranke (DGM e.\u202fV.), MITONET e.\u202fV. (stellvertretende Vorsitzende), Kompetenznetzwerk f\u00fcr Diagnostik und Therapie mitochondrialer Erkrankungen, World Muscle Society (WMS). <b>H.\u00a0Seidel<\/b>: A.\u00a0Finanzielle Interessen: H.\u00a0Seidel gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Angestellter Internist (Bonn), Transfusionsmediziner (Dortmund), Centrum f\u00fcr Blutgerinnungsst\u00f6rungen (CBT), Bonn, Dortmund | Mitgliedschaften: GTH, DGTI, BDDH, ISTH. <b>R.\u00a0Conrad<\/b>: A.\u00a0Finanzielle Interessen: R.\u00a0Conrad gibt an, dass kein finanzieller Interessenkonflikt besteht. \u2013 B.\u00a0Nichtfinanzielle Interessen: Oberarzt und Forschungsleiter, Klinik und Poliklinik f\u00fcr Psychosomatische Medizin und Psychotherapie, Universit\u00e4tsklinikum Bonn | Mitgliedschaften: Deutsches Kollegium f\u00fcr Psychosomatische Medizin (DKPM), Deutsche Gesellschaft f\u00fcr Eye Movement Desensitization and Reprocessing (EMDR), Deutsche Gesellschaft f\u00fcr Hypnose und Hypnotherapie (DGH), Deutsche Gesellschaft f\u00fcr Psychiatrie, Neurologie und Nervenheilkunde (DGPPN). <b>M.\u00a0M\u00fccke<\/b>: A.\u00a0Finanzielle Interessen: Bezahlter Referent: Rare Disease Academy, Firma Takeda ehemals Shire. \u2013 B.\u00a0Nichtfinanzielle Interessen: Leiter des Zentrums f\u00fcr seltene Erkrankungen, Universit\u00e4tsklinikum Bonn, niedergelassener Allgemeinmediziner, Praxis PD Dr. M\u00fccke, Bonn | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Allgemeinmedizin und Familienmedizin (DEGAM), Ad-hoc-Ausschuss \u201eAusbildung zum Arzt\/Hochschulen und Medizinische Fakult\u00e4ten\u201c der \u00c4rztekammer Nordrhein.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}